Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Study Summary

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

Conditions

Alzheimer Disease Alzheimer Disease, Early Onset

Interventions / Drugs

ARO-MAPT-SC Placebo

View on ClinicalTrials.gov ↗

Sponsor

ARWR

Arrowhead Pharmaceuticals

RNAi Therapeutics

D36/100

Study Details

Enrollment112 participants

Primary Completion—

Lead SponsorArrowhead Pharmaceuticals

Data Retrieved2026-04-11 02:54:36.141233+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.